Skip to content

Price / book at other companies

Amgen logo
AmgenAMGN
20.6×-6.3×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
2.6×+0.2×
Immunome logo
ImmunomeIMNM
4.2×+2.3×
Vera Therapeutics logo
Vera TherapeuticsVERA
5.7×+2.9×
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
+0.6×
Incyte logo
IncyteINCY
3.3×+0.1×

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.25B+1,531%
Enterprise value$2.33B+874%
P/S40.5×+38.9×

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Calculated from Nektar Therapeutics’s reported figures.

Based on the most recent quarter.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's price / book.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nektar Therapeutics's price / book?
Nektar Therapeutics (NKTR) reported price / book of 3.6× in Q1 2026.
How has Nektar Therapeutics's price / book changed year-over-year?
Nektar Therapeutics's price / book decreased by 61.1% year-over-year, from 9.2× to 3.6×.
What is the long-term trend for Nektar Therapeutics's price / book?
Over 5 years (2020 to 2025), Nektar Therapeutics's price / book has grown at a 26.9% compound annual growth rate (CAGR), from 2.9× to 9.6×.
What does price / book mean?
Market capitalization at the quarter end divided by shareholders' equity. The premium (or discount) the market assigns to the company's book equity.